Skip to main content

Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ: REGN · IEX Real-Time Price · USD
18.95 (2.98%)
At close: Dec 8, 2021 4:00 PM
0.83 (0.13%)
After-hours:Dec 8, 2021 7:02 PM EST
Market Cap70.34B
Revenue (ttm)13.54B
Net Income (ttm)7.00B
Shares Out107.54M
EPS (ttm)62.53
PE Ratio10.46
Forward PE13.64
Ex-Dividend Daten/a
Previous Close635.09
Day's Range633.19 - 655.83
52-Week Range441.00 - 686.62
Price Target714.25 (+9.2%)
Earnings DateNov 4, 2021

About REGN

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent i...

IPO DateApr 2, 1991
CEOLeonard Schleifer
Stock ExchangeNASDAQ
Ticker SymbolREGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 24 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is 714.25, which is an increase of 9.21% from the latest price.

Price Target
(9.21% upside)
Analyst Consensus: Buy


New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to...

New England Journal of Medicine p ublishes p ositive Phase 3 Dupixent ® (dupilumab) results in children with moderate-to-severe asthma

8 hours ago - GlobeNewsWire

New England Journal of Medicine Publishes Positive Phase 3 Dupixent® (dupilumab) Results in Children with Moderate-to...

TARRYTOWN, N.Y. and PARIS, Dec. 8, 2021 /PRNewswire/ --  Dupixent significantly reduced severe asthma attacks and improved lung function and asthma control in children aged 6 to 11 years with uncontroll...

8 hours ago - PRNewsWire

5 Biotech Stocks To Watch In The Stock Market Today

Should investors be watching these biotech stocks with all the current focus on the Omicron Covid variant?

2 days ago - Stockmarketcom

COVID-19 Vaccine & Drug Makers Gear Up to Fight Omicron

The Omicron variant ignites fears that currently available COVID-19 vaccines and treatments could be less effective against it. MRNA, PFE, BNTX, REGN and JNJ are some of the industry players gearing up ...

5 days ago - Zacks Investment Research

Regeneron to Participate in H.C. Wainwright & Co. Virtual Event

TARRYTOWN, N.Y., Dec. 3, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is scheduled to participate in a virtual fireside chat at the H.C.

5 days ago - PRNewsWire

Regeneron: Surfing on Covid, With More Under the Surface

Regeneron has made billions from its Covid-19 drug, and it has new drugs like Dupixent that could make many billions more. The post Regeneron: Surfing on Covid, With More Under the Surface appeared firs...

6 days ago - InvestorPlace

People should get vaccinated and boosted, Dr. Fauci says

Dr. Anthony Fauci, National Institute of Allergy and Infectious Diseases, speaks from the White House on the omicron variant, which was discovered in a patient in California.

1 week ago - CNBC Television

Which companies see growth opportunities during rising Covid concerns

Michael Yee, Jefferies biotech analyst and managing director, joins 'Power Lunch' to discuss how company stocks are reacting to rising omicron concerns and which are the best to play with Covid concerns.

1 week ago - CNBC Television

Why Are Stocks Down Today? 4 Things to Know.

Why are stocks down today? It seems that fears over tapering, inflation and the omicron variant are worrying investors on Tuesday.

Other symbols:MRNA
1 week ago - InvestorPlace

HC Wainwright Sees 'Buying Opportunity' For This COVID-19 Antibody Stock After Sell-Off

H.C. Wainwright recommends using the selloff today for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) as a buying opportunity. The analyst keeps a Buy rating on Regeneron with an $844 price target.

1 week ago - Benzinga

Regeneron warns its antibody cocktail may be less effective against Omicron variant

Regeneron -- which markets REGEN-COV, the most widely used monoclonal antibody therapy to treat COVID-19 in the US -- cautioned that further studies are needed to determine whether the Omicron variant c...

1 week ago - New York Post

Regeneron CEO says Covid antibody cocktail may be less effective against omicron variant

Regeneron Pharmaceuticals' Covid-19 antibody cocktail, and similar drugs, could be less effective against the omicron coronavirus variant, the company said.

1 week ago - CNBC

Regeneron CEO: We'll likely have to constantly adapt our antibody cocktail

Dr. Leonard Schleifler, founder and CEO of Regeneron, joins "Squawk Box" to discuss the company's monoclonal antibody treatment and the omicron variant.

1 week ago - CNBC Television

Regeneron reports antibody treatment is less effective against omicron variant

CNBC's Meg Tirrell reports on the latest headlines from drugmakers and vaccine makers on the omicron variant.

1 week ago - CNBC Television

Regeneron: Antibody cocktail is less effective against omicron

The "Squawk Box" team discusses a report from Regeneron that its antibody treatment is less effective against the omicron variant.

1 week ago - CNBC Television

Regeneron Extends Hearing Loss Gene Therapy pact With Decibel

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has extended the research term of its collaboration with Decibel Therapeutics Inc (NASDAQ: DBTX) to discover and develop gene therapies for hearing loss.  Th...

2 weeks ago - Benzinga

Why Regeneron's Results for Its COVID Antibody Therapy Won't Boost Sales Much

The therapy will likely face stiff competition from more convenient COVID-19 pills.

2 weeks ago - The Motley Fool

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Nov. 16, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Evercore ISI 4th Annual HealthCONx Conference at 9:15 a.m.

3 weeks ago - PRNewsWire

Regeneron (REGN), Roche Get EC Nod for COVID-19 Cocktail

Regeneron (REGN) and partner Roche win the European Commission's approval for antibody cocktail to treat and prevent COVID-19.

3 weeks ago - Zacks Investment Research

Regeneron Listed on Dow Jones Sustainability World Index for Third Consecutive Year

TARRYTOWN, N.Y., Nov. 15, 2021 /PRNewswire/ -- DJSI World highlights the most sustainable companies around the world by industry Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been recognized as a g...

3 weeks ago - PRNewsWire

Regeneron Announces $3 Billion Share Repurchase Program

TARRYTOWN, N.Y., Nov. 12, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that its Board of Directors authorized a share repurchase program of up to $3 billion of the...

3 weeks ago - PRNewsWire

Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail

The European Commission (EC) has approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and Ronapreve in the European Union (EU) and other cou...

3 weeks ago - Benzinga

Regeneron (REGN)-Roche COVID-19 Cocktail Gets Positive CHMP Opinion

Regeneron (REGN) and partner Roche obtain a positive opinion from CHMP for their antibody cocktail for the treatment of non-hospitalized patients with confirmed COVID-19 and to prevent the disease.

3 weeks ago - Zacks Investment Research

Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19

TARRYTOWN, N.Y., Nov. 12, 2021 /PRNewswire/ -- EC marketing authorization follows approvals in Japan, Australia and the UK Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Europea...

3 weeks ago - PRNewsWire

EU Regulator Backs Regeneron-Roche's COVID-19 Drug

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) REGEN-COV. The casirivimab a...

3 weeks ago - Benzinga